Richard A D Carano Selected Research

Richard A D Carano Research Topics

Disease

25	Neoplasms (Cancer) 11/2019 - 03/2004
6	Inflammation (Inflammations) 01/2021 - 06/2007
5	Neoplasm Metastasis (Metastasis) 01/2017 - 11/2009
5	Colorectal Neoplasms (Colorectal Cancer) 01/2015 - 03/2004
4	Atrophy 01/2022 - 01/2017
3	Disease Progression 01/2022 - 06/2007
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 09/2013 - 06/2010
3	Experimental Arthritis 01/2011 - 06/2007
2	Multiple Sclerosis 01/2022 - 01/2022
2	Alzheimer Disease (Alzheimer's Disease) 01/2019 - 08/2017
2	Tauopathies 01/2019 - 12/2018
2	Hypoxia (Hypoxemia) 11/2017 - 08/2012
2	Rheumatoid Arthritis 01/2017 - 01/2011
2	Prostatic Neoplasms (Prostate Cancer) 10/2015 - 07/2013
2	Melanoma (Melanoma, Malignant) 05/2011 - 11/2010
2	Arthritis (Polyarthritis) 01/2011 - 06/2007
2	Infections 05/2010 - 03/2010
1	Asthma (Bronchial Asthma) 01/2021
1	Cough 01/2021
1	Edema (Dropsy) 01/2021
1	Pain (Aches) 01/2021
1	Amyloid Plaque 01/2019
1	Amyloidosis 01/2019
1	Neurodegenerative Diseases (Neurodegenerative Disease) 08/2017
1	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 08/2017
1	Fibrosis (Cirrhosis) 01/2017
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2017
1	Hemorrhage 01/2017
1	Carcinogenesis 10/2015
1	Obesity 07/2015
1	Type 2 Diabetes Mellitus (MODY) 07/2015
1	Weight Loss (Weight Reduction) 07/2015
1	Lung Neoplasms (Lung Cancer) 02/2013
1	Residual Neoplasm 02/2013
1	Hypophosphatemia 01/2013
1	Primitive Neuroectodermal Tumors (PNET) 08/2012
1	Osteosarcoma (Osteogenic Sarcoma) 09/2011
1	Adenocarcinoma 06/2010

Drug/Important Bio-Agent (IBA)

10	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2017 - 07/2008
7	Biomarkers (Surrogate Marker)IBA 01/2022 - 11/2009
5	AntibodiesIBA 12/2018 - 04/2010
4	Proteins (Proteins, Gene)FDA Link 09/2011 - 10/2002
3	LigandsIBA 01/2018 - 08/2012
2	ocrelizumabIBA 01/2022 - 01/2022
2	Complement System Proteins (Complement)IBA 01/2019 - 06/2007
2	CollagenIBA 01/2018 - 01/2018
2	Phosphotransferases (Kinase)IBA 08/2017 - 04/2017
2	Bevacizumab (Avastin)FDA Link 01/2015 - 11/2009
2	Protons (Proton)IBA 07/2008 - 03/2004
1	GDC-0334IBA 01/2021
1	Transient Receptor Potential ChannelsIBA 01/2021
1	Amyloid (Amyloid Fibrils)IBA 01/2021
1	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 10/2019
1	Complement C3 (C3 Complement)IBA 01/2019
1	ProteomeIBA 12/2018
1	Collagenases (Collagenase)FDA Link 01/2018
1	atezolizumabIBA 01/2018
1	ProdrugsIBA 11/2017
1	Tirapazamine (SR 4233)IBA 11/2017
1	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 04/2017
1	Mitogen-Activated Protein Kinase 3IBA 04/2017
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 04/2017
1	Mitogen-Activated Protein KinasesIBA 04/2017
1	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 04/2017
1	Toll-Like Receptors (Toll-Like Receptor)IBA 04/2017
1	fenebrutinibIBA 01/2017
1	Ferrosoferric Oxide (Magnetite)FDA Link 01/2017
1	Contrast MediaIBA 01/2017
1	Pyruvic Acid (Pyruvate)IBA 10/2015
1	NAD (NADH)IBA 10/2015
1	Niacinamide (Nicotinamide)FDA LinkGeneric 10/2015
1	Lactic Acid (Lactate)FDA LinkGeneric 10/2015
1	Nicotinamide PhosphoribosyltransferaseIBA 10/2015
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 10/2015
1	Insulin (Novolin)FDA Link 07/2015
1	AdiponectinIBA 07/2015
1	1- (4- ((2- (2- aminopyrimidin- 5- yl)- 7- methyl- 4- morpholinothieno(3,2- d)pyrimidin- 6- yl)methyl)piperazin- 1- yl)- 2- hydroxypropan- 1- oneIBA 11/2013
1	Oxygen (Dioxygen)IBA 11/2013
1	Notch ReceptorsIBA 07/2013
1	MTOR InhibitorsIBA 07/2013
1	TOR Serine-Threonine KinasesIBA 07/2013
1	ErbB Receptors (EGF Receptor)IBA 02/2013
1	Sunitinib (Sutent)FDA Link 08/2012
1	Deubiquitinating EnzymesIBA 09/2011
1	Neuropilin-1IBA 03/2011
1	CGI 1746IBA 01/2011
1	CytokinesIBA 01/2011
1	AutoantibodiesIBA 01/2011
1	Agammaglobulinaemia Tyrosine KinaseIBA 01/2011
1	InflammasomesIBA 05/2010
1	Blocking AntibodiesIBA 04/2010
1	Placenta Growth FactorIBA 04/2010
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 04/2010

Therapy/Procedure

16	Therapeutics 01/2021 - 11/2009
2	Drug Therapy (Chemotherapy) 04/2015 - 02/2013
1	Immunotherapy 10/2019
1	Aftercare (After-Treatment) 01/2018
1	Bioreactors (Bioreactor) 10/2015
1	Transplantation 07/2013
1	Intravenous Administration 11/2010